Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $707,400.00 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS opened at $17.57 on Friday. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35. The business has a 50 day simple moving average of $16.45 and a 200 day simple moving average of $18.90.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The firm had revenue of $2.28 million during the quarter, compared to the consensus estimate of $2.20 million. Equities analysts expect that NewAmsterdam Pharma will post -2.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NAMS has been the subject of several research analyst reports. Needham & Company LLC started coverage on NewAmsterdam Pharma in a research report on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price objective for the company. Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $33.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the second quarter worth about $38,000. Sei Investments Co. lifted its holdings in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after purchasing an additional 8,087 shares during the last quarter. Wolverine Asset Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after buying an additional 8,394 shares during the period. Rosalind Advisors Inc. bought a new stake in shares of NewAmsterdam Pharma during the second quarter worth approximately $194,000. Finally, Yarbrough Capital LLC bought a new stake in NewAmsterdam Pharma in the 1st quarter valued at $567,000. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.